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Introduction {#sec005}
============

Sudden cardiac death (SCD) caused by ventricular fibrillation (VF) during acute myocardial infarction (MI) is a major cause of cardiovascular mortality.\[[@pone.0226936.ref001]--[@pone.0226936.ref003]\] Susceptibility to VF during acute ischemia is undoubtedly multifactorial and modulated by several factors, including autonomic dysregulation, electrolyte disturbance, hemodynamic dysfunction, inherited factors, and various environmental influences.\[[@pone.0226936.ref001],[@pone.0226936.ref004],[@pone.0226936.ref005]\]

Seasonal variation has been reported in the incidence of sudden cardiac arrest (SCA) and sudden death/SCD,\[[@pone.0226936.ref006]--[@pone.0226936.ref010]\] typically with a winter peak and a summer nadir. Exposure to cold weather is considered the main factor influencing this seasonality.\[[@pone.0226936.ref007]\] However, these previous epidemiological studies are limited by differences in the definition of SCD (none had VF recording available) used and the fact that they often included SCD cases occurring in the setting of different cardiac pathologies (i.e., etiological heterogeneity in substrate for VF). Nevertheless, these seasonal patterns indicate the presence of seasonal external factors, such as viral infections, that could trigger VF. While several studies indicate consistent association between viral infections and MI,\[[@pone.0226936.ref011]--[@pone.0226936.ref013]\] there is weaker evidence of an association between viral exposure and cardiac arrhythmias and SCA\[[@pone.0226936.ref014],[@pone.0226936.ref015]\]. A genome-wide association study in the Dutch AGNES (Arrhythmia Genetics in the NEtherlandS) population showed that the most significant association with VF during first ST-elevation myocardial infarction (STEMI) is localized at chromosome 21q21 (SNP: rs2824292, odds ratio = 1.78, 95% CI 1.47--2.13, P = 3.3x10^-10^).\[[@pone.0226936.ref016]\] Interestingly, the closest gene to this locus is the *CXADR* gene, which encodes the coxsackie (a member of enterovirus (EV)) and adenovirus receptor (CAR-receptor).\[[@pone.0226936.ref016]\] Furthermore, electrophysiological studies and molecular analyses on CAR in mice showed that CAR is a novel modifier of ventricular conduction and arrhythmia vulnerability in the setting of myocardial ischemia.\[[@pone.0226936.ref017]\] Moreover, we and others previously showed that SCD victims and individuals resuscitated from SCA experienced generalized fatigue and influenza-like symptoms in the days to weeks before SCD/SCA,\[[@pone.0226936.ref018]--[@pone.0226936.ref020]\] supporting the role of viral exposure in susceptibility to VF during an acute MI. Several studies have shown that influenza vaccine protects against acute MI and heart failure.\[[@pone.0226936.ref021]--[@pone.0226936.ref023]\] In addition, because EV and influenza epidemics can be accurately and reliably forecast, such forecasts could advise individuals with chest pain and flu-like symptoms to seek medical care in an early phase during outbreaks.

In this study, the relationship between monthly/weekly incidence of EV or influenza virus and the risk of VF during a first STEMI was investigated by correlating Danish surveillance data of EV and influenza exposure in the general population over a period of almost 7 years with individual data on VF risk before primary percutaneous coronary intervention (PPCI) among first STEMI patients.

Methods {#sec006}
=======

Study population {#sec007}
----------------

The study population consisted of all consecutive patients aged between 18--80 years with a first STEMI (n = 4,659) admitted to the invasive catheterization laboratory between January 1, 2010 and October 31, 2016 at the Copenhagen University Hospital, Rigshospitalet. Rigshospitalet covers all of eastern Denmark (2.6 million citizens), which corresponds to 45% of the entire Danish population. The STEMI patients were divided in two groups. The main outcome was if VF occurred within the first 12 hours of symptoms of STEMI before PPCI. We included both out-of-hospital and in-hospital cardiac arrest with STEMI and VF (82% out-of-hospital and 17% during emergency care or in hospital (at arrival)). Patients with out-of-hospital cardiac arrest were included on admission to the PCI center after resuscitation by trained emergency medical service personnel. VF had to occur before the guided catheter insertion for PPCI; all VF cases had ECG-documented VF. In addition, all medical reports (emergency and hospital records) and discharge summaries were reviewed to verify patients as VF cases. Patients who were non-Danish citizens (n = 180) were excluded.

The study was approved by the Danish Data Protection Agency (No. 2012-58-0004). Registers were available in an anonymous setup; individual patients were not identifiable because the personal identification numbers were encrypted. We obtained approval from the Danish Patient Safety Authority to gain information on medical reports and discharge summaries (No. 3-3013-2277/1). In Denmark, ethical approval is not required for retrospective, register-based studies.

Data sources {#sec008}
------------

A unique and permanent personal identification number is assigned to all residents in Denmark. This number is used in all Danish health and administrative registries and enables individual-level linkage between all nationwide registries unambiguously.

[Fig 1](#pone.0226936.g001){ref-type="fig"} shows the data collection. We used data from the electronic Eastern Danish Heart Registry comprising detailed clinical data on all consecutive STEMI patients undergoing cardiac catherization and coronary revascularization in Eastern Denmark. The electronic Eastern Danish Heart Registry includes detailed clinical data on all patients undergoing coronary angiography, such as baseline demographics, angiographic findings, and procedure characteristics from the PPCI.\[[@pone.0226936.ref024]\] All these data were routinely registered by the PCI operator and assistants in the catheterization laboratory during the PPCI. This registry was further linked to the following three nationwide administrative registries via the personal identification number. (1) The Danish Civil Registration System contains daily changes in the vital status of all residents, and no historical data are deleted.\[[@pone.0226936.ref025]\] (2) The Danish National Patient Registry holds information on all admissions to hospitals since 1978 and outpatient visits since 1995, coded according to the International Classification of Diseases (ICD)-8 and ICD-10.\[[@pone.0226936.ref026]\] Information on date of admission, date of discharge, and diagnoses of comorbidities was recorded for every STEMI patient prior to index STEMI. (3) The Danish Registry of Medicinal Product Statistics, which registers all prescriptions dispensed from Danish pharmacies since 1995. Each drug is coded according to the international Anatomical Therapeutic Chemical (ATC) classification system, and the registry includes data on type of drug, strength, quantity dispensed, and date of dispensing \[[@pone.0226936.ref027]\], which has been shown to be accurate.\[[@pone.0226936.ref028]\]

![Study population selection and data collection.](pone.0226936.g001){#pone.0226936.g001}

Because we were not able to obtain the actual viral exposure on an individual level for the study population, we used monthly and weekly virus incidences at the national level as a proxy for the viral exposure. The virology data were obtained from *Statens Serum Institute*, a Danish governmental public health and research institute operating within the Danish Ministry of Health. We utilized weekly and monthly surveillance data for EV and influenza from the Danish National Microbiology Database (2010--2016), which captures all positive laboratory test results conducted at hospital laboratories in Denmark.\[[@pone.0226936.ref029]\] This surveillance system monitors national trends in circulating viral infections and collects data on EV and influenza at the genotype level, as well as patient demographic information and clinical details, including symptoms and date of symptom onset. During the study period of 82 months, 2,704 individuals were diagnosed with EV in the general population. Due to higher incidence of influenza, we calculated the number of influenza events per week, and during the study period of 358 weeks, 19,742 individuals were diagnosed with influenza. The weekly and monthly viral exposure data were then combined and merged with the Eastern Danish Heart Registry using the date of PPCI ([Fig 1](#pone.0226936.g001){ref-type="fig"}). The data points comprised monthly and weekly counts of individuals who tested positive for EV and influenza, respectively, obtained from patients who presented to GPs, as well as from hospitalized patients.

Statistical analysis {#sec009}
--------------------

Patient characteristics at index STEMI are summarized as the mean and standard deviation (SD) or proportion according to VF status and compared with t-tests and chi-square tests as appropriate.

Separate multivariable logistic regressions were performed for the association of EV and influenza exposure on the day of STEMI and the risk of VF. The models included EV and influenza incidences as continuous variables and were adjusted for week number as a nominal variable with 52 levels and calendar year. Moreover, we performed a full adjusted model, including, week number, calendar year, as well as sex, age, hypertension, atrial fibrillation (AF), chronic kidney disease, Killip class, culprit lesion, preprocedural TIMI-flow, smoking, and previous history of angina. Reported were odds ratios (OR) and accompanying 95% confidence intervals (CI). The likelihood ratio test was used to test the significance of week number.

In a subset of patients (n = 807),\[[@pone.0226936.ref030]\] we had detailed data on whether the patient had experienced generalized fatigue and flu-like symptoms within the last week prior to the STEMI. A logistic regression model was fitted on this subset. The model was adjusted for week number, calendar year, sex, age, hypertension, AF, chronic kidney disease, Killip class, culprit lesion, preprocedural TIMI-flow, smoking, and previous history of angina.

Analyses were performed using SAS (version 9.4, SAS Institute Inc, Cary, NC, USA) and R.\[[@pone.0226936.ref031]\]

Results {#sec010}
=======

Clinical characteristics {#sec011}
------------------------

Between January 2010 and October 2016, there were 4,659 consecutively enrolled first STEMI patients (age 18--80 years) at Rigshospitalet in Copenhagen, of whom 581 (12%) had VF before PPCI. The clinical characteristics at the time of STEMI are shown in [Table 1](#pone.0226936.t001){ref-type="table"}. Patients with VF were more likely to be men, be a current smoker, have a history of AF and experience no angina compared with STEMI patients without VF. Furthermore, the proportion on anticoagulant therapy was higher among patients with VF compared with patients without, likely due to the higher degree of AF ([Table 1](#pone.0226936.t001){ref-type="table"}). The angiographic and other presenting characteristics at the time of STEMI according to VF status are outlined in [Table 1](#pone.0226936.t001){ref-type="table"}. Patients with VF had shorter times from symptom onset to PPCI, lower left ventricular ejection fraction, were more likely to have anterior infarctions with left anterior descending artery occlusions, and had lower pre-PCI TIMI flow and higher Killip class.

10.1371/journal.pone.0226936.t001

###### Patient characteristics at index ST-elevation myocardial infarction according to ventricular fibrillation.

![](pone.0226936.t001){#pone.0226936.t001g}

  Variable                                                                  STEMI with VF (n = 581)   STEMI without VF (n = 4078)   P-value
  ------------------------------------------------------------------------- ------------------------- ----------------------------- ----------
  Sex, men, n (%)                                                           468 (80.6)                3113 (76.3)                   0.028
  Age at STEMI, years, mean (SD)                                            59.9 (10.3)               60.7 (10.9)                   0.079
  Age category, n (%)                                                                                                               
      \<35                                                                  \<5                       36 (0.9)                      0.374
      35--49                                                                110 (18.9)                697 (17.1)                    
      50--64                                                                263 (45.3)                1790 (43.9)                   
      \> = 65                                                               205 (35.3)                1555 (38.1)                   
  BMI, kg/m^2^, mean (SD)                                                   27.9 (14.5)               27.3 (9.9)                    0.267
  Missing, n                                                                87                        120                           
  Smoking, n (%)                                                                                                                    
      Current                                                               285 (56.8)                1899 (51.1)                   0.025
      Never                                                                 96 (19.1)                 894 (24.1)                    
      Past                                                                  121 (24.1)                921 (24.8)                    
      Missing, n                                                            79                        364                           
  Family history of ischemic heart disease, n (%)                           190 (70.1)                2312 (65.5)                   0.143
  Missing, n                                                                310                       550                           
  Canadian Cardiovascular Society (CCS) grading of angina pectoris, n (%)                                                           
      CCS I-II                                                              33 (7.6)                  445 (11.2)                    0.032
      CCS III-IV                                                            12 (2.8)                  72 (1.8)                      
      No angina                                                             390 (89.7)                3462 (87.0)                   
      Missing, n                                                            146                       99                            
  **COMORBIDITIES**                                                                                                                 
  Hypertension, n (%)                                                       100 (17.2)                620 (15.2)                    0.233
  Diabetes, n (%)                                                           40 (6.9)                  328 (8.0)                     0.375
  Atrial fibrillation, n (%)                                                33 (5.7)                  102 (2.5)                     \< 1e-04
  Hypercholesterolemia, n (%)                                               26 (4.5)                  238 (5.8)                     0.218
  Peripheral vascular disease, n (%)                                        22 (3.8)                  103 (2.5)                     0.105
  Stroke, n (%)                                                             19 (3.3)                  122 (3.0)                     0.812
  Congestive heart failure, n (%)                                           15 (2.6)                  86 (2.1)                      0.562
  Chronic kidney disease, n (%)                                             10 (1.7)                  98 (2.4)                      0.382
  Liver disease, n (%)                                                      9 (1.5)                   61 (1.5)                      1.000
  Malignancy, n (%)                                                         39 (6.7)                  367 (9.0)                     0.080
  **PHARMACOTHERAPY---3 months before**                                                                                             
  Renin-angiotensin-system blockers, n (%)                                  113 (19.4)                728 (17.9)                    0.379
  Statins, n (%)                                                            63 (10.8)                 444 (10.9)                    1.000
  Calcium channel blockers, n (%)                                           61 (10.5)                 440 (10.8)                    0.889
  Antidiabetics, n (%)                                                      40 (6.9)                  351 (8.6)                     0.187
  Beta-blockers, n (%)                                                      59 (10.2)                 328 (8.0)                     0.100
  Acetylsalicylic acid, n (%)                                               42 (7.2)                  290 (7.1)                     0.987
  Diuretics (combi), n (%)                                                  37 (6.4)                  254 (6.2)                     0.969
  Thiazide, n (%)                                                           35 (6.0)                  233 (5.7)                     0.837
  Loop diuretics, n (%)                                                     20 (3.4)                  98 (2.4)                      0.177
  Potassium supplements, n (%)                                              16 (2.8)                  85 (2.1)                      0.376
  Anti-coagulantia, n (%)                                                   26 (4.5)                  69 (1.7)                      \< 1e-04
  Anti-adrenergic drugs, n (%)                                              \<5                       58 (1.4)                      0.211
  Spironolactone, n (%)                                                     6 (1.0)                   26 (0.6)                      0.418
  **PPCI VARIABLES**                                                                                                                
  Time from symptom onset to PPCI, min, mean (SD)                           172.0 (146.8)             268.1 (503.8)                 \< 1e-04
      Missing, n                                                            30                        93                            
  Pre-procedural LVEF, n (%)                                                                                                        
      LVEF \< = 35                                                          142 (24.4)                238 (5.8)                     \< 1e-04
      LVEF \>35                                                             189 (32.5)                895 (21.9)                    
      Missing                                                               250 (43.0)                2945 (72.2)                   
  Infarct location, n (%)                                                                                                           
      Anterior                                                              262 (45.1)                1616 (39.6)                   \< 1e-04
      Non-anterior                                                          212 (36.5)                2213 (54.3)                   
      Missing, n                                                            107                       249                           
  Culprit lesion, n (%)                                                                                                             
      LAD                                                                   302 (54.1)                1732 (42.6)                   \< 1e-04
      Non-LAD                                                               256 (45.9)                2336 (57.4)                   
      Missing                                                               23                        10                            
  Pre-procedural TIMI flow, n (%)                                                                                                   
      TIMI 0-I                                                              21 (3.8)                  87 (2.2)                      0.015
      TIMI II-III                                                           172 (31.2)                1478 (36.6)                   
      Missing, n                                                            30                        40                            
  Killip class, n (%)                                                                                                               
      Killip Class I                                                        454 (83.0)                3711 (94.6)                   \< 1e-04
      Killip Class \>I                                                      93 (17.0)                 213 (5.4)                     
      Missing, n                                                            34                        154                           

Seasonality of infections and VF during first STEMI {#sec012}
---------------------------------------------------

During the study period in the general population, 2,704 individuals were diagnosed with EV and 19,742 with influenza. Graphs of seasonal patterns of influenza and EV and number of VF cases in the setting of first STEMI over the study time are shown in [Fig 2](#pone.0226936.g002){ref-type="fig"}. Influenza showed strong winter and spring seasonality (week 40 to week 20), with a maximum observed during the first 10 weeks of the year. EV was detected year-round but tended to peak, as expected, during late summer and fall months. There was no clear seasonality of VF during STEMI.

![Number of influenza, enterovirus (EV) and ventricular fibrillation (VF) cases per week and month by year.](pone.0226936.g002){#pone.0226936.g002}

Results from the logistic regression analyses for VF before PPCI are summarized in [Fig 3](#pone.0226936.g003){ref-type="fig"}. We found no association between EV and VF (OR 1.00, 95% CI 0.99--1.02) or influenza and VF (OR 1.00, 95% CI 1.00--1.00). We also found no association between week number and VF (p-value 0.94 for EV model and 0.89 for influenza model), confirming the lack of seasonality in the risk of VF found in [Fig 2](#pone.0226936.g002){ref-type="fig"}.

![Odds ratio for ventricular fibrillation during first ST-elevation myocardial infarction.](pone.0226936.g003){#pone.0226936.g003}

*Subanalysis*--generalized fatigue and flu-like symptoms prior to event {#sec013}
-----------------------------------------------------------------------

In a subset of the patients (n = 807),\[[@pone.0226936.ref030]\] we had detailed data on whether the patient had experienced generalized fatigue and flu-like symptoms within the last week prior to the STEMI. Compared with the STEMI patients without VF prior to PPCI (n = 520), the VF cases (n = 287) had significantly more generalized fatigue and flu-like symptoms within 7 days before STEMI (14% vs. 5%, p\<0.0001, OR 3.39, 95% CI 1.76--6.54). In addition, the majority of the symptoms were reported for STEMI patients during influenza season (defined as week 40 to week 20) (76% vs. 24%, p = 0.024).

Discussion {#sec014}
==========

Main findings {#sec015}
-------------

This cohort study is the first to investigate the relationship between viral exposure and VF risk at first STEMI before PPCI. The study consecutively enrolled 4,659 patients with STEMI (aged 18--80 years), of whom 12% developed VF prior to PPCI. It was found that VF patients had experienced more generalized fatigue and flu-like symptoms within 7 days before STEMI compared with the patients without VF (OR 3.39, 95% CI 1.76--6.54). The expected winter peak and summer nadir of VF were not observed. After correlating Danish viral exposure surveillance data with individual data on VF risk among first STEMI, no such relationship was found between EV or influenza exposure and occurrence of VF. Therefore, there is no support for an association between higher levels of EV or influenza and high VF prevalence.

Seasonality of VF and association with viral infections {#sec016}
-------------------------------------------------------

The seasonality of MI, ventricular arrhythmias, and SCA/SCD has for many decades been the focus of epidemiology studies, as seasonality may suggest etiological factors.\[[@pone.0226936.ref006]--[@pone.0226936.ref010]\] Because all patients in our study had a first STEMI, we were able to examine the seasonality and relationship of viral exposure with VF independently of its association with STEMI. Most,\[[@pone.0226936.ref008],[@pone.0226936.ref032]\] but not all,\[[@pone.0226936.ref033]\] studies showed a seasonal variation of SCD, with a peak in winter (December and January) and a reduction during the summer months (from June through September). A link between viral infection of the heart (myocarditis) and sudden cardiac death has long been recognized.\[[@pone.0226936.ref034]\] At least 20 different viruses, including EV, have been implicated in myocarditis.\[[@pone.0226936.ref035]\] Although most patients infected with EV remain asymptomatic or only experience flu-like symptoms, the role of EV as one of the most common causes of viral myocarditis is well-established.\[[@pone.0226936.ref036]\] Evidence for a role of EV infection in the modulation of cardiac electrical function and pro-arrhythmia is the fact that myocarditis is one of the most common findings at autopsy in young adults who died of SCD,\[[@pone.0226936.ref037]\] and patients with serious ventricular arrhythmias and survivors of SCD had prevalent detection of EV RNA in their endomyocardial biopsies, suggesting a role of EV in ventricular arrhythmias and SCD\[[@pone.0226936.ref038]\]. Although we did not find an association between influenza and VF risk during STEMI, substantial evidence has been gathered to support the effect of influenza among MI patients.\[[@pone.0226936.ref013],[@pone.0226936.ref039]\] These findings are consistent across studies using various measures for viral exposure, such as influenza activity at the population level through surveillance data,\[[@pone.0226936.ref040],[@pone.0226936.ref041]\] as well as at the individual level with laboratory-confirmed infection\[[@pone.0226936.ref013]\]. The latter is preferable, and Kwong et al. found in a self-controlled case-series study that laboratory-confirmed influenza in the week before MI was associated with increased risk of MI.\[[@pone.0226936.ref013]\] Incidence ratio for acute MI during the 7-day risk interval compared with the control interval was 6.05 (95% CI 3.86--9.50). These data suggest that influenza-like illness can cause MI.\[[@pone.0226936.ref013]\]

In support of a role for viral infection in the modulation of VF susceptibility, a common variant genome-wide association study in the Dutch AGNES population, which compared individuals with and without VF in the setting of a first acute STEMI,\[[@pone.0226936.ref016]\] identified a VF susceptibility locus at chromosome 21q21 (rs2824292) close to the *CXADR* gene. While this observation is intriguing, the association was not replicated in two similar MI populations.\[[@pone.0226936.ref042],[@pone.0226936.ref043]\] The lack of replication might have been due to the necessity of exposure to EV that may vary by location and time of the year. However, CAR protein has a long-recognized role as viral receptor in the pathogenesis of viral myocarditis,\[[@pone.0226936.ref044]\] a physiologic role for the receptor in localization of connexin 45 at the intercalated disks of the cardiomyocytes in the atrioventricular node, and a role in conduction of the cardiac impulse \[[@pone.0226936.ref017],[@pone.0226936.ref045],[@pone.0226936.ref046]\].

Although there is substantial evidence supporting the role of influenza in CVD mortality and SCA/SCD,\[[@pone.0226936.ref015],[@pone.0226936.ref047]\] we did not find an association between influenza and VF risk during STEMI. There are several possible reasons for this discrepancy in associations. First, many studies were designed to investigate overall influenza mortality or CVD mortality rather than SCA/SCD\[[@pone.0226936.ref047]\]. Second, most studies included different cardiac causes of SCA and SCD with consequent etiological heterogeneity, and no study has specifically investigated VF in the setting of an acute first MI. The role of influenza infection may be different with different underlying cardiac causes of SCA/SCD. Lastly, some studies used SCA/SCD as a surrogate of VF, and thus some cases of sudden death due to bradyarrhythmic or noncardiac causes may have been misclassified.

Strength and limitations {#sec017}
------------------------

There are several strengths of the current study. Our data collection process was comprehensive, and we were able to adjust the VF risk for multiple significant covariates. Despite these strengths, there were also some limitations that should be noted. First, we did not have individual viral exposure data. Second, it employed an ecological study design. As such, it was not possible to examine the exact exposure history of each individual. In addition, the community burden of viral infections is substantially underestimated in surveillance data, as most patients with EV or influenza do not seek medical care. However, because the underreporting is unlikely to vary over time, there is no evidence that this would substantially bias our results. Furthermore, the EV incidence was on a monthly basis, and an option could have been to interpolate the EV data as weekly incidences. However, the data points for EV were too scarce to obtain reliable incidence estimates. Third, there is a concern for recall bias regarding the symptoms prior to event. Patients were questioned about their symptoms during the admission to hospital. However, we have previously found that cases experience less angina within the last 12 months compared with controls.\[[@pone.0226936.ref030]\] Fourth, even though data were prospectively collected, we performed retrospective analyses. Fifth, patients who died outside of hospitals were not included, and the results may not be generalizable to patients who do not survive to reach the hospital. Lastly, although the strength of this study is the completeness of data via link between clinical data (the Eastern Danish Heart Registry) and Danish nationwide registries the validity of our data depends largely on the accuracy of coding. It has been documented that the coding of risk factors has high validity and specificity in the Danish National Patient Registry.\[[@pone.0226936.ref026]\]

In this study, we focused on seasonal viral infections, but several other CVD risk factors display seasonal variation. Obesity, increased fat intake, reduced physical activity, and higher blood pressure and serum cholesterol levels are more prevalent in winter. However, traditional risk factors including hypertension, hypercholesterolemia, and smoking were not independently associated with VF risk during STEMI in our cohort.\[[@pone.0226936.ref024],[@pone.0226936.ref030]\] Future studies should base infection status on the individual STEMI patient to detect whether active infection might increase risk for VF during acute STEMI.

Clinical implications {#sec018}
---------------------

Due to low survival after VF and the risk of neurological deficits in patients who survive cardiac arrest, prevention is key in addressing this important public health problem. In this study, 14% of the VF cases experienced flu-like symptoms during the week before their sudden cardiac arrest, and these symptoms may provide an opportunity for medical intervention to prevent some cases of VF during acute ischemia, especially in high-risk patients.

Conclusion {#sec019}
==========

There was no clear seasonality of VF during STEMI; after correlating Danish viral exposure surveillance data with individual data on VF risk among first STEMI, no relationship was found between EV or influenza exposure and occurrence of VF. Even though we found that VF patients experienced more generalized fatigue and flu-like symptoms within 7 days before STEMI compared with the patients without VF, our data do not support the hypothesis that higher levels of EV and influenza are associated with high VF prevalence.

10.1371/journal.pone.0226936.r001

Decision Letter 0

den Uil

Corstiaan

Academic Editor

© 2020 Corstiaan den Uil

2020

Corstiaan den Uil

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

11 Dec 2019

Seasonality of Ventricular Fibrillation at First Myocardial Infarction and Association with Viral Exposure

PONE-D-19-29659

Dear Dr. Glinge,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Corstiaan den Uil

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors should be congratulated for this excellent work. Even if the results are negative, the tested hypothesis is of major importance and those findings will be helpful for appropriately guide future research in the field. In the study, the authors examine the influence of seasonality and association of increased enterovirus and influenza activity in the community with the risk of ventricular fibrillation (VF) during first ST-elevation myocardial infarction. Based on a large STEMI cohort and on individual-level linkage of data from Danish nationwide registries, they identified all consecutive STEMI patients admitted to acute angiography and Primary PCI (PPCI) at Rigs Hospitalet Copenhagen between January 2010 and October 2016. The cohort where linked to information on monthly/weekly surveillance data on entro - and influenza virus from the Danish National Microbiology Database. Of 4659 consecutively enrolled STEMI patients, 581 (12%) had VF before PPCI. The VF patients experienced more fatigue and flu-like symptoms 7 days prior to the STEMI event than the non-VF patients from the cohort, but no significant association between enterovirus, week-number and influenza virus exposure

was found. Based on the results the authors conclude that there was no seasonality during STEMI, and that there were no relationship between enterovirus and influenza virus exposure and occurrence of VF before PPCI in STEMI patients. The topic is of great interest since SCA still accounts for more than half of cardiovascular mortality, and because acute coronary artery disease represents the majority of underlying causes. Methodology is robust, paper very well written. Although findings are negative they add substantially to the literature and undoubtedly will help others to go forward in this field.
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